胸腺肽α1对肝细胞癌患者热消融术后免疫功能及预后的影响

摘要

Objective:To investigate the effects of thymosin α1 on the immune function and prognosis of hepato-cellular carcinoma after thermal ablation.Methods:Clinical data of 80 patients were retrospectively analyzed.They were diagnosed with hepatocellular carcinoma of BCLC-A and treated from 2010 to 2012 at the First Affiliated Hos-pital of Henan University of Traditional Chinese Medicine.40 of them were treated with microwave ablation or radio-frequency ablation with thymosin α1(observation group),and the other 40 were just treated with microwave ablation or radiofrequency ablation(control group).Subset of T cells and long-term efficacies were compared between them. Results:The ratios of peripheral blood CD4 +/CD8 +after 1 year in observation group were significantly higher than control group(P<0.01).The 1-,3-,5-year overall survival rates were 97.5%,90.0% and 75.0% for the patients in observation group,and in control group they were 97.5%,80.0% and 57.5%. The 1 -,3 -,5 -year recurrence -free survival rates were 97.5%,72.5% and 47.5%for the patients in observation group,and in control group they were 95.0%,52.5% and 27.5%.There were significant differences in 5-year overall survival rate and recurrence free survival rate between the two groups(P=0.09,P=0.06).Conclusion:Postoperative thy-mosin α1 therapy can improve postoperative immune function of hepatocellular carcinoma,thus significantly prolong recurrence-free survival rate and overall survival rate.%目的:探讨胸腺肽α1对原发性肝癌患者热消融术后免疫功能及预后的影响.方法:回顾性收集2010年至2012年在河南中医药大学第一附属医院的BCLC-A期原发性肝癌患者热消融术后共80例,按热消融术后是否使用胸腺肽α1分为观察组及对照组(各40例),比较两组患者的免疫功能及远期治疗效果.结果:与对照组相比,观察组消融1年后仍存在较高的CD4 +/CD8 +比值(1.34 ± 0.36 vs 0.64 ± 0.26,P<0.01).观察组1年生存率、3年生存率及5年生存率分别为97.5%、90.0%及75.0%,对照组1年生存率、3年生存率及5年生存率分别为97.5%、80.0%及57.5%,二者的5年生存率比较差异有统计学意义(P=0.09).观察组1年无瘤生存率、3年无瘤生存率及5年无瘤生存率分别为97.5%、72.5%及47.5%,对照组1年无瘤生存率、3年无瘤生存率及5年无瘤生存率分别为95.0%、52.5%及27.5%,二者的5年无瘤生存率比较差异有统计学意义(P=0.06).结论:胸腺肽α1能改善原发性肝癌热消融后患者的CD4 +/CD8 +比值,提高患者的无瘤生存率及总生存率.